Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40AS8 | ISIN: US98987D3008 | Ticker-Symbol:
NASDAQ
06.06.25 | 16:44
0,646 US-Dollar
-0,60 % -0,004
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ZYVERSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ZYVERSA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ZYVERSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.05.ZyVersa Therapeutics, Inc. - 8-K, Current Report2
20.05.ZyVersa's IC 100 shows promise in Parkinson's treatment5
20.05.ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases112Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein...
► Artikel lesen
ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln
13.05.ZyVersa Therapeutics GAAP EPS of -$0.733
12.05.ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress125KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease...
► Artikel lesen
12.05.ZyVersa Therapeutics, Inc. - 10-Q, Quarterly Report1
07.05.ZyVersa progresses with obesity inflammation treatment9
07.05.ZyVersa Therapeutics: ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update3
29.04.ZyVersa Therapeutics Publishes Data Supporting Potential Of Its Inflammasome ASC Inhibitor IC 1001
29.04.ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease4
24.04.ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status50WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...
► Artikel lesen
10.04.Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?2
08.04.ZyVersa CEO outlines progress in kidney disease drug development4
08.04.ZyVersa-CEO erläutert Fortschritte bei der Entwicklung von Medikamenten gegen Nierenerkrankungen4
08.04.ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)162WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...
► Artikel lesen
07.04.ZyVersa Therapeutics, Inc. - 8-K, Current Report1
04.04.ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders1
27.03.ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update170KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR...
► Artikel lesen
27.03.ZyVersa Therapeutics, Inc. - 10-K, Annual Report2
18.03.ZyVersa's IC 100 shows promise in OAC treatment study1
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1